Hepatitis B (HBV) — Deal Benchmarks & Valuation
Market Analysis
Hepatitis B (HBV) is one of the most actively transacted indications in infectious disease licensing. Phase 2 deals for hepatitis b (hbv) carry a median total deal value of $2.5B, with upfront payments ranging from $377M to $898M. The recommended deal structure allocates approximately 26% to upfront payments and 74% to milestones.
Milestone structures for hepatitis b (hbv) deals allocate $403M to development milestones, $422M to regulatory milestones, and $1.0B to commercial milestones. Royalty rates range from 8.3% to 16.6% at the base tier, with tiered escalation reaching 12.3%-20.6% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for hepatitis b (hbv) licensing?
What royalty rates are standard for hepatitis b (hbv) deals?
How are hepatitis b (hbv) deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.